Use of biosimilars in the treatment of rheumatoid arthritis An overview
Morf H, Witte T (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1007/s00393-021-01129-6
Abstract
Biologics have been an integral part of the treatment of rheumatoid arthritis for approximately 20 years. As patents for pharmaceuticals generally expire after 10 years, in recent years biosimilars have come onto the market. Many studies have shown that they are an equivalent alternative to the reference drug with comparable safety and efficacy. In some cases, they even showed lower rates of adverse drug reactions compared to the reference drugs. Furthermore, considerable costs can be saved by biosimilars, which amount to an annual three-digit million sum in Germany alone. Large regional differences in the prescription frequency of biosimilars in Germany can be identified, which are also reflected in the savings potential. A switch to a biosimilar is possible and desirable with the involvement of the patient. In this sense, the initial prescription of a biosimilar instead of the reference drug is also to be advocated.
Involved external institutions
Germany (DE)How to cite
APA:
Morf, H., & Witte, T. (2021). Use of biosimilars in the treatment of rheumatoid arthritis An overview. Zeitschrift für Rheumatologie. https://dx.doi.org/10.1007/s00393-021-01129-6
MLA:
Morf, Harriet, and Thorben Witte. "Use of biosimilars in the treatment of rheumatoid arthritis An overview." Zeitschrift für Rheumatologie (2021).
BibTeX: Download